期刊文献+

丁丙诺菲透皮贴联合普瑞巴林治疗老年带状疱疹后神经痛的临床观察 被引量:1

Clinical Effects of Combined Buprenorphine Transdermal Patch and Pregabalin on Gerontic Postherpetic Neuralgia
下载PDF
导出
摘要 目的观察丁丙诺菲透皮贴联合普瑞巴林治疗老年带状疱疹后神经痛的临床效果。方法 60例老年带状疱疹后神经痛患者随机分为试验组和对照组。试验组:丁丙诺菲透皮贴联合普瑞巴林;对照组:单独应用口服普瑞巴林。治疗8周后记录两组患者用药前、用药后2周、4周、8周的疼痛评分(visual analogue scale,VAS)、睡眠评分、普瑞巴林日剂量及不良反应发生率。结果两组患者治疗后VAS评分明显低于治疗前(P<0.01),治疗后4周及8周试验组VAS评分明显低于对照组(P<0.05);用药治疗后两组患者睡眠质量明显改善(P<0.05);联合应用丁丙诺菲透皮贴后可明显减少试验组普瑞巴林的用量(P<0.05);联合应用丁丙诺菲透皮贴可以显著减少普瑞巴林相关不良反应头晕、嗜睡的发生率(P<0.05)。结论丁丙诺菲透皮贴联合普瑞巴林对老年带状疱疹后神经痛患者的临床效果优于单独应用普瑞巴林,不良反应较小。 Objective To observed the effect of buprenorphine transdermal patches combined with pregabalin in gerontic patients with PHN. Methods 60 patients were divided into experimental group and control group randomly. Patients of experimental group were treated with buprenorphine transdermal patches combined with pregabalin. The control group were orally administered pregabalin simply. The pain scores (VAS scores), sleep scores, doses of pregabalin and adverse reactions at each time point were recorded. Results There were a significant decline in VAS scores and sleep scores after treatment in 2 groups(P〈0.01). Compared with the control group, the VAS scores and the dose of pregabalin were significantly lower at 4, 8 weeks after treatment(P〈0.05). The incidence of dizzy and drowsiness were higher in control group(P〈0.05), but there were no significant difference in the incidence of other side effects. Conclusion The combination of buprenorphine transdermal patches and pregabalin is effective and safe for the gerontic patients with PHN.
出处 《中国医药指南》 2015年第21期1-2,共2页 Guide of China Medicine
基金 国家自然科学基金资助项目(81271371)
关键词 带状疱疹后神经痛 丁丙诺菲透皮贴 普瑞巴林 Postherpetic neuralgia Buprenorphine transdermal patches Pregabalin
  • 相关文献

参考文献11

  • 1Sampathkumar P, Drage LA,Martin DP.Herpes zoster (shingles) and postherpetie neuralgia[J].Mayo Clin Proe,2009,84(3):274-280.
  • 2施小妹,宋涛,王秋石,崔文瑶,奚奇,吴兆奇.胸椎旁注射治疗带状疱疹后神经痛[J].实用药物与临床,2012,15(2):70-72. 被引量:11
  • 3Nalamachu S,Morley-Forster EDiagnosing and managing posthe- rpetic neuralgia[J].Drugs Aging,2012,29( 11 ):863 -869.
  • 4Baron R.Mechanisms of disease: neuropathic pain-a clinical persp- ective[J].Nat Clin Pratt Neurol,2006,2(2):95-106.
  • 5Stacey BR,Dworkin RH,Murphy K,et al.Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial[J].Pain Med,2008,9(8): 1202-1208.
  • 6Gilden D,Cohrs R,Hayward A,et al.Chronic varicella-zoster virus ganglionitis-a possible cause of postherpetic neuralgia[J].J Neurov- irol,2003,9(3):404-407.
  • 7Belliotti TR,Capiris T, Ekhato IV, et al.Structure-Activity Relation- ships of Pregabalin and Analogues That Target the ct 2- ~ Protein [J].J Med Chem,2005,48(7):2294-2307.
  • 8Dworkin RH,O'Connor AB,Backonja M,et al.Pharmacologic mana- gement of neuropathic pain: evidence-based recommendations[J]. Pain,2007,132(3) :237-251.
  • 9Sabatowski R,Galvez R, Cherry DA,et al.Pregabalin reduces pain and improves sleep and mood disturbances in patients with post- herpetic neuralgia: results of a randomised,placebo-controlled clinical trial[J].Pain,2004,109(1):26-35.
  • 10徐建国,王楠.中重度疼痛治疗药丁丙诺啡透皮贴剂的药理作用及临床评价[J].中国新药杂志,2013,22(23):2717-2720. 被引量:16

二级参考文献30

  • 1Tajima K,Iseki M,Inada E. The effects of early nerve blocks for prevention of postherpetic neuralgia and analysis of prognostic factors [ J ]. Masui ,2009,58 (2) : 153-159.
  • 2Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France[ J]. Clin Infect Dis,2001,33 ( 1 ) :62-69.
  • 3Pappagallo M, Haldey EJ. Pharmacological management of postherpetic Neuralgia[ J ]. CNS Drugs,2003,17 ( 11 ) :771.
  • 4Daemen MA, Kurvers HA, Kitslaar PJ, et al. Neurogenic inflammation in an animal model of neuropathic pain[ J]. Neurol Res, 1998,20( 1 ) :41-45.
  • 5Wang J, Ren Y, Zou X, et al. Sympathetic influence on capsaicin-evoked enhancement of dorsal root reflexes in rats [ J ]. J Neurophysio,2004,92 (4) :2017-2026.
  • 6Ren Y.,Zou X,Fang L, et al. Sympathetic modulation of activity in Adelta-and C-primary nociceptive afferents after intradermal injection of capsaicin in rats [ J ]. J Neurophysiol, 2005,93 ( 1 ) :365-377.
  • 7Tomoki N, Takashi M, Koichi Y. Comparison between neurotropin and mepivacaine for stellate ganglion injection [ J ]. J Anesth, 2006,20 : 240 -24.
  • 8HANS G,ROBERT D.Transdermal buprenorphine-a critical appraisal of its role in pain management[J].J Pain Res,2009,2:117-134.
  • 9PLOSKER GL.Buprenorphine 5,10 and 20 mug/h transdermal patch:a review of its use in the management of chronic non-malignant pain[J].Drugs,2011,71(18):2491-2509.
  • 10VADIVELU N,HINES RL.Management of chronic pain in the elderly:focus on transdermal buprenorphine[J].Clin Interv Aging,2008,3(3):421-430.

共引文献24

同被引文献2

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部